December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

262.56 USD -2.59 (-0.98%)
Streaming Delayed Price Updated: 7:36 AM EST, Jan 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
From GlobeNewswire News Releases
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
Tags MIT Community Lab Education
From 3BL Media: Corporate Social Responsibility, Energy and Health News
The Critical Role of Community Health: Bringing Necessary Services to Key Demographics
Tags NASDAQ:BIIB Health & Healthcare coronavirus
From 3BL Media: Corporate Social Responsibility, Energy and Health News
New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS
From GlobeNewswire News Releases
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
From GlobeNewswire News Releases
Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
Samsung Bioepis Co., Ltd. announced today that the primary endpoints have been met in the randomized, double-masked, phase 3 trial comparing the efficacy, safety and immunogenicity of SB11, a... 
From Business Wire News Releases
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
From GlobeNewswire News Releases
Biogen Prices $3.0 Billion of Senior Unsecured Notes
From GlobeNewswire News Releases
Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics
From GlobeNewswire News Releases
Thinking about trading options or stock in Biogen, Walt Disney, Nvidia, Roku, or Starbucks?
InvestorsObserver issues critical PriceWatch Alerts for BIIB, DIS, NVDA, ROKU, and SBUX. 
From PR Newswire
Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank
From GlobeNewswire News Releases
Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment
Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir's... 
From PR Newswire
Sangamo Announces Closing of Biogen Collaboration Agreement
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global licensing... 
From Business Wire News Releases
Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
From GlobeNewswire News Releases
Thinking about trading options or stock in Abbott Laboratories, Autodesk, Amazon.com, Biogen, or Microsoft?
InvestorsObserver issues critical PriceWatch Alerts for ABT, ADSK, AMZN, BIIB, and MSFT. 
From PR Newswire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
From GlobeNewswire News Releases
Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
From GlobeNewswire News Releases
S&P 500 buybacks up 3.2% in Q4 2019; Full Year 2019 down 9.6% from record 2018, as companies brace for a more volatile 2020
- Q4 2019 share repurchases reached $181.6 billion - 3.2% higher than Q3 2019, and 18.6% lower than the record Q4 2018. 
From PR Newswire
Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World
From GlobeNewswire News Releases
Thinking about trading options or stock in Biogen, Clorox, Centene, Netflix, or Walmart?
InvestorsObserver issues critical PriceWatch Alerts for BIIB, CLX, CNC, NFLX, and WMT. 
From PR Newswire
Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19
From GlobeNewswire News Releases
Thinking about trading options or stock in Apple, Anthem, Biogen, Netflix, or NVIDIA?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ANTM, BIIB, NFLX, and NVDA. 
From PR Newswire
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
From GlobeNewswire News Releases
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and... 
From Business Wire News Releases
Thinking about trading options or stock in Biogen, Costco, NVIDIA, Insulet Corp, or Tesla?
InvestorsObserver issues critical PriceWatch Alerts for BIIB, COST, NVDA, PODD, and TSLA. 
From PR Newswire
Thinking about buying stock in Biogen, Clorox, Cronos Group, e.l.f. Beauty, or IBM?
InvestorsObserver issues critical PriceWatch Alerts for BIIB, CLX, CRON, ELF, and IBM. 
From PR Newswire
Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
From GlobeNewswire News Releases
CAMP4 Announces Collaboration to Discover Novel Targets to Address Neurodegenerative and Neurological Diseases
CAMP4 Therapeutics today announced a collaboration with Biogen Inc. (Nasdaq: BIIB) aimed at addressing neurodegenerative and neurological diseases. 
From Business Wire News Releases
Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
-- Biogen, Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics join founders BioMarin and Invitae to expand access for children under eight -- 
From PR Newswire
Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
Catalyst to receive $15 million upfront and is eligible to receive an additional $340 million in milestones and tiered royalties up to low double digits 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.